PMC:7784830 / 6614-7004
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 120 | 46-52 | Species | denotes | People | Tax:9606 |
| 121 | 164-183 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
| 122 | 185-206 | Chemical | denotes | chloroquine phosphate | MESH:C023676 |
| 123 | 208-217 | Chemical | denotes | ribavirin | MESH:D012254 |
| 124 | 223-230 | Chemical | denotes | arbidol | MESH:C086979 |
| 125 | 298-309 | Chemical | denotes | chloroquine | MESH:D002738 |
| 126 | 311-318 | Chemical | denotes | arbidol | MESH:C086979 |
| 127 | 320-330 | Chemical | denotes | remdesivir | MESH:C000606551 |
| 128 | 336-347 | Chemical | denotes | favipiravir | MESH:C462182 |
| 138 | 124-132 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T57 | 12-231 | Sentence | denotes | National Health Commission of the People’s Republic of China has provided some preferred drugs for treatment of COVID-19 that include interferon alpha, lopinavir/ritonavir, chloroquine phosphate, ribavirin, and arbidol. |
| T58 | 232-356 | Sentence | denotes | Some of the drugs that are presently at clinical trials stage are chloroquine, arbidol, remdesivir, and favipiravir [40,41]. |